Condition: Neoplasms, Brain · Glioblastoma Multiforme · Glioblastoma of Cerebellum · Sponsor: M.D. Anderson Cancer Center
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD
This description comes directly from the study's public registry record.
Kara Kachurak, CRNP · 832-750-5661l · kgkachurak@mdanderson.org
Gregory K Friedman, MD · gkfriedman@mdanderson.org
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | Active Not Recruiting |
| Siteman Cancer Center at Washington University | St Louis, Missouri, United States | Active Not Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03911388